CTLA4 and melanoma: This interaction of inhibition of angiogenesis with immune response has also been shown in patients with renal cell cancer and melanoma, in whom the addition of bevacizumab to anti-programmed death ligand 1 (anti-PD-L1) or anti-CTLA4 therapy increased the T cell response.18,19